TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
Theriva Biologics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.20−0.00 (-1.54%)
Close on Oct 19, 2026
- Market cap
- $9.39M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.2164 (−51.39%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $9.39M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -177.81%
Fundamentals
- EPS, diluted
- -$2.08
- Free cash flow
- -$16.70M
- Diluted shares
- 46M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$11.93M
Net income
–
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months